A form of Candidiasis has emerged which manifests symptoms that are often systemic and cause considerable discomfort. It usually originates as an overgrowth of the fungal form of Candida occurring in the lower gastrointestinal tract. Frequent courses of steroid and antibiotic medications, oral contraceptives and diet high in yeast-containing foods, sugars, and refined carbohydrates are all known to encourage Candida overgrowth.
The ELISA test offers high sensitivity and specificity in detecting early stage Polysystemic Chronic Candidiasis (P.C.C.) thus allowing prompt initiation of therapy.
The Immunodiffusion test confirms late stage P.C.C. when antibody levels have risen significantly. Both tests are run on each patient sample.
The Assay: comprises of two tests designed to assist physicians in diagnosing P.C.C. The procedures are:
Immunodiffusion: The Candida Immunodiffusion test is an FDA approved procedure to detect precipitating antibodies to both Candida cytoplasmic and mannan antigen fractions. The test makes use of agarose gel to reveal bands of precipitating antibodies (if present) in the patient's serum. Test results are reported as negative or positive; if positive, the number of bands is reported.
Enzyme-Linked Immunoabsorbent Assay (ELISA): uses the cytoplasmic protein of Candida albicans as the antigen for detecting specific IgG. The results are indicated as titers, 1:100 to greater than 1:5000. Titers 1:3000 and greater are positive for P.C.C.